0001140361-23-041197.txt : 20230824
0001140361-23-041197.hdr.sgml : 20230824
20230824213031
ACCESSION NUMBER: 0001140361-23-041197
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230822
FILED AS OF DATE: 20230824
DATE AS OF CHANGE: 20230824
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gline Matthew
CENTRAL INDEX KEY: 0001750094
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40782
FILM NUMBER: 231203658
MAIL ADDRESS:
STREET 1: C/O UROVANT SCIENCES, INC.
STREET 2: 5151 CALIFORNIA AVENUE, SUITE 250
CITY: IRVINE
STATE: CA
ZIP: 92617
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Roivant Sciences Ltd.
CENTRAL INDEX KEY: 0001635088
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981173944
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: CLARENDON HOUSE, 2 CHURCH STREET
CITY: HAMILTON HM11
STATE: D0
ZIP: HM11
BUSINESS PHONE: 441-295-5950
MAIL ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
4
1
form4.xml
X0508
4
2023-08-22
0001635088
Roivant Sciences Ltd.
ROIV
0001750094
Gline Matthew
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY
LONDON
X0
SW1H 0DB
UNITED KINGDOM
true
true
CEO
false
Common Shares
2023-08-22
4
J
0
11015
10.83
D
1039644
D
Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.
The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline
2023-08-24